1α(OH)D3 (ETALPHA)® treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders
- 24 April 2009
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 39 (1) , 35-38
- https://doi.org/10.1111/j.1600-0609.1987.tb00160.x
Abstract
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1.alpha.(OH)D3, up to 4 .mu.g daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 .mu.g daily of 1.alpha.(OH)D3 for a prolonged period up to 17 wk. The treatment with 1.alpha.(OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patients with increased specific receptor binding capacity. The maximum tolerable dose of 1.alpha.(OH)D3 varied individually, but was in the range of 2-4 .mu.g daily.Keywords
This publication has 17 references indexed in Scilit:
- THE USEFULNESS OF 1,25‐DIHYDROXY‐VITAMIN D3 (1,25(OH)2 vit D3) IN THE TREATMENT OF IDIOPATHIC MYELOFIBROSISBritish Journal of Haematology, 1986
- Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas.BMJ, 1985
- 1,25‐Dihydroxyvitamin D 3 and the regulation of the differentiation and function of macrophages and granulocytesThe International Journal of Cell Cloning, 1985
- TREATMENT OF ADVANCED MYELODYSPLASTIC SYNDROME WITH ALFACALCIDOLThe Lancet, 1984
- CLINICAL EVIDENCE FOR 1,25-HYDROXYCHOLECALCIFEROL ACTION IN MYELOFIBROSISThe Lancet, 1984
- 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells.The Journal of cell biology, 1984
- Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metaboliteNature, 1983
- 1,25-Dihydroxyvitamin D 3 Receptors in Human LeukocytesScience, 1983
- ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MANThe Lancet, 1974